01—Abstract
Summary
Summary of the 8-K filed May 1, 2026. Cited figures are marked; the original filing is the authoritative source.
On May 1, 2026, Quest Diagnostics (NYSE: DGX) disclosed via Form 8-K that it priced a public offering of $500 milliona aggregate principal amount of 5.000% senior notes due 2036 under its existing shelf registration statement.
The offering was priced on April 27, 2026, with closing expected on May 6, 2026, subject to customary conditions. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC are the underwriters named in the Underwriting Agreement dated April 27, 2026.
The company stated that it intends to use net proceeds for general corporate purposes, which may include repaying indebtedness. Notably, the filing specifically identifies the company's $500 millionb 3.45% Senior Notes maturing June 1, 2026 as a potential repayment target. This suggests the new issuance is at least partly a refinancing of a near-term maturity, which would largely keep total debt roughly unchanged while extending the maturity profile to 2036 and replacing a 3.45% coupon with a 5.000% coupon.
For investors, the transaction is a routine debt refinancing rather than a signal of new strategic activity. The higher coupon implies increased annual interest expense on the refinanced amount, and the filing does not disclose use of proceeds for acquisitions, buybacks, or other growth initiatives. The 8-K contains no new operating, financial performance, or guidance information.
02—Key points
Key Highlights
- Quest Diagnostics priced a $500 million offering of 5.000% senior notes due 2036 under its existing shelf registration on April 27, 2026.
- Closing of the offering is expected on May 6, 2026, subject to customary closing conditions.
- Proceeds may be used to repay the company's $500 million 3.45% Senior Notes maturing June 1, 2026, indicating a likely refinancing of near-term debt.
- The new notes carry a higher coupon (5.000%) than the maturing notes (3.45%), implying higher annual interest cost on the refinanced amount.
- Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC served as underwriters under the Underwriting Agreement dated April 27, 2026.
- The filing contains no new information on operating results, guidance, acquisitions, or capital returns.
03—Questions
Frequently Asked Questions
What is the size and terms of the new debt offering?
Quest Diagnostics priced $500 million aggregate principal amount of 5.000% senior notes due 2036 on April 27, 2026, issued under its existing shelf registration statement.
Why is Quest issuing new notes?
The company says the net proceeds will be used for general corporate purposes, which may include repaying indebtedness. The filing specifically names its $500 million 3.45% Senior Notes maturing June 1, 2026 as a potential repayment target.
When will the offering close and when will proceeds be received?
The company expects to receive net proceeds upon closing on May 6, 2026, subject to customary closing conditions.
Does this offering change Quest's debt level or financial outlook?
If the proceeds are used to repay the June 2026 notes, total debt would be largely unchanged, but the maturity profile would be extended to 2036 and annual interest cost would rise because the new coupon (5.000%) exceeds the retired coupon (3.45%). The filing does not include updated financial guidance or results.
Who are the underwriters for the offering?
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC, acting on behalf of themselves and other named underwriters, entered into the Underwriting Agreement dated April 27, 2026.
04—Continue